Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Abstract Background KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer. We investigated the association of biomarkers with clinical...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-01-01
coleção:	Breast Cancer Research
Assuntos:	Tumor biomarkers Trastuzumab emtansine Pertuzumab HER2-positive breast cancer KRISTINE
Acesso em linha:	https://doi.org/10.1186/s13058-022-01587-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!